itinai content — All you need

Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics

Ralph Brattsand April 27, 2024 Pharmaceuticals (Basel). 2024 Apr 15;17(4):503. doi: 10.3390/ph17040503. ABSTRACT The introduction of inhaled corticosteroids (ICSs) changed over a few decades the treatment focus of mild-to-moderate asthma from bronchodilation to reduction in inflammation. This was achieved by inhaling a suitable corticosteroid (CS), giving a high, protracted airway concentration at a low total… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer’s Disease Risk: A Retrospective Cohort Proof-of-Concept Study

Tiffany W Chow April 27, 2024 Pharmaceuticals (Basel). 2024 Mar 22;17(4):408. doi: 10.3390/ph17040408. ABSTRACT Brain somatic gene recombination (SGR) and the endogenous reverse transcriptases (RTs) that produce it have been implicated in the etiology of Alzheimer’s disease (AD), suggesting RT inhibitors as novel prophylactics or therapeutics. This retrospective, proof-of-concept study evaluated the incidence of AD… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases

Diana Trujillo-Benítez April 27, 2024 Pharmaceutics. 2024 Apr 12;16(4):532. doi: 10.3390/pharmaceutics16040532. ABSTRACT Recently, we reported a new fibroblast activation protein (FAP) inhibitor radiopharmaceutical based on the 99mTc-((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl) pyrrolidin-2-yl) boronic acid (99mTc-HYNIC-D-Alanine-BoroPro)(99mTc-HYNIC-iFAP) structure for tumor microenvironment SPECT imaging. This research aimed to synthesize 68Ga-[2,2′,2″,2‴-(2-(4-(2-(5-(((S)-1-((S)-2-boronopyrrolidin-1-yl)-1-oxopropan-2-yl)carbamoyl)pyridin-2-yl)hydrazine-1-carbothioamido)benzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid] (68Ga-DOTA-D-Alanine-BoroPro)(68Ga-iFAP) as a novel radiotracer for PET imaging and evaluate its… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
Beneficial Effect of Heat-Killed Lactic Acid Bacterium Lactobacillus johnsonii No. 1088 on Temporal Gastroesophageal Reflux-Related Symptoms in Healthy Volunteers: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study

Yasuhiko Komatsu April 27, 2024 Nutrients. 2024 Apr 20;16(8):1230. doi: 10.3390/nu16081230. ABSTRACT A randomized, placebo-controlled, double-blind, parallel-group clinical study was conducted to examine the effects of ingesting a heat-killed lactic acid bacterium, Lactobacillus johnsonii No. 1088 (LJ88) on temporal gastroesophageal reflux-related symptoms in healthy volunteers. A total of 120 healthy Japanese volunteers of both sexes,… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
The Association between Circulating Cytokines and Body Composition in Frail Patients with Cardiovascular Disease

Ilona Korzonek-Szlacheta April 27, 2024 Nutrients. 2024 Apr 20;16(8):1227. doi: 10.3390/nu16081227. ABSTRACT The burden of cardiovascular disease and the percentage of frail patients in the aging population will increase. This study aims to assess the circulating levels of several cytokines in frail patients. This is an ancillary analysis of the FRAPICA trial. The ratio of… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
Association between Homocysteine and Vitamin D Levels in Asymptomatic Korean Adults

Yun-Ah Lee April 27, 2024 Nutrients. 2024 Apr 13;16(8):1155. doi: 10.3390/nu16081155. ABSTRACT An increased homocysteine level is a risk factor for cardiovascular disease, venous thromboembolism, cerebrovascular disease, and chronic kidney disease. In addition, vitamin D deficiency is associated with coronary artery disease and metabolic disorders. The present study included data from 1375 adults (895 men… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
Principles in the Management of Glioblastoma

Domingos Roda April 27, 2024 Genes (Basel). 2024 Apr 17;15(4):501. doi: 10.3390/genes15040501. ABSTRACT Glioblastoma, the most aggressive and common malignant primary brain tumour, is characterized by infiltrative growth, abundant vascularization, and aggressive clinical evolution. Patients with glioblastoma often face poor prognoses, with a median survival of approximately 15 months. Technological progress and the subsequent improvement… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
Reproductive Outcomes in Young Women with Early-Stage Cervical Cancer Greater than 2 cm Undergoing Fertility-Sparing Treatment: A Systematic Review

Antonio D’Amato April 27, 2024 Medicina (Kaunas). 2024 Apr 6;60(4):608. doi: 10.3390/medicina60040608. ABSTRACT Background and Objectives: Despite advancements in detection and treatment, cervical cancer remains a significant health concern, particularly among young women of reproductive age. Limited data exists in the literature regarding fertility-sparing treatment (FST) of cervical cancers with tumor sizes greater than 2… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
GNB1 Encephalopathy: Clinical Case Report and Literature Review

Matas Nasvytis April 27, 2024 Medicina (Kaunas). 2024 Apr 1;60(4):589. doi: 10.3390/medicina60040589. ABSTRACT GNB1 encephalopathy is a rare genetic disease caused by pathogenic variants in the G Protein Subunit Beta 1 (GNB1) gene, with only around 68 cases documented worldwide. Although most cases had been caused by de novo germline mutations, in this case, the… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase
Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC)

Anna Grenda April 27, 2024 Int J Mol Sci. 2024 Apr 10;25(8):4208. doi: 10.3390/ijms25084208. ABSTRACT Lung cancer has become a major public health concern, standing as the leading cause of cancer-related deaths worldwide. Among its subtypes, small-cell lung cancer (SCLC) is characterized by aggressive and rapid growth, poor differentiation, and neuroendocrine features. Typically, SCLC is… →

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase